Prolonged isolated thrombocytopenia after hematopoietic stem cell transplantation: morphologic correlation

被引:33
作者
Bielski, M
Yomtovian, R
Lazarus, HM
Rosenthal, N
机构
[1] Case Western Reserve Univ, Univ Hosp Cleveland, Ireland Canc Ctr, Dept Pathol, Cleveland, OH 44106 USA
[2] Case Western Reserve Univ, Univ Hosp Cleveland, Ireland Canc Ctr, Dept Med, Cleveland, OH 44106 USA
关键词
isolated; thrombocytopenia; hematopoietic stem cell transplantation; megakaryocyte;
D O I
10.1038/sj.bmt.1701499
中图分类号
Q6 [生物物理学];
学科分类号
071011 ;
摘要
Prolonged isolated thrombocytopenia, defined as recovery of other cell counts with continuous dependence on platelet transfusions for greater than 90 days after hematopoietic stem cell transplantation (HSCT), develops in approximately 5% of patients who undergo HSCT, Although the clinical conditions associated with prolonged isolated thrombocytopenia have been studied, a systematic review of bone marrow biopsies has not been performed and the pathophysiologic basis has not been defined. We reviewed all HSCT at one center from 1990 to 1995 (n = 454) and found 12 cases that met criteria for prolonged isolated thrombocytopenia (incidence = 12/454 or 3%), Bone marrow core biopsies from 12 patients with prolonged isolated thrombocytopenia were reviewed to determine cellularity, numbers of megakaryocytes, the presence of atypical forms, and clusters of megakaryocytes, These marrow megakaryocyte counts were compared to age and disease matched controls, and 11 normal donors. Patients (aged 1-56 Sears, mean 32 years) who underwent HSCT (four sibling HLA-identical, five autologous bone marrow, three autologous peripheral stem cell) with prolonged isolated thrombocytopenia had a statistically significant lower absolute megakaryocyte count in bone marrow biopsies performed before transplantation and more than 30 days after transplantation compared to control patients (aged 4 months to 50 years, mean 31 years) who underwent HSCT (four sibling HLA-identical, four autologous bone marrow, four autologous peripheral stem cell) for similar conditions. No apparent differences were seen in size of megakaryocytes, nuclear-cytoplasmic ratios, or clustering of megakaryocytes, Overall marrow cellularities were similar in the three groups, These findings suggest that decreased differentiation of megakaryocytes from stem cells, rather than ineffective platelet production or peripheral destruction of platelets, causes prolonged isolated thrombocytopenia in HSCT patients. Low megakaryocyte counts prior to HSCT may be a useful prognostic indicator, as this feature was associated with the development of prolonged isolated thrombocytopenia.
引用
收藏
页码:1071 / 1076
页数:6
相关论文
共 33 条
  • [1] ANASETTI C, 1989, BLOOD, V73, P1054
  • [2] A PHASE-II STUDY OF HIGH-DOSE CYCLOPHOSPHAMIDE, THIOTEPA, AND CARBOPLATIN WITH AUTOLOGOUS MARROW SUPPORT IN WOMEN WITH MEASURABLE ADVANCED BREAST-CANCER RESPONDING TO STANDARD-DOSE THERAPY
    ANTMAN, K
    AYASH, L
    ELIAS, A
    WHEELER, C
    HUNT, M
    EDER, JP
    TEICHER, BA
    CRITCHLOW, J
    BIBBO, J
    SCHNIPPER, LE
    FREI, E
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1992, 10 (01) : 102 - 110
  • [3] BONE-MARROW TRANSPLANTATION
    ARMITAGE, JO
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1994, 330 (12) : 827 - 838
  • [4] Long-term engraftment failure after marrow ablation and autologous hematopoietic reconstitution: Differences between peripheral blood stem cell and bone marrow recipients
    Bentley, SA
    Brecher, ME
    Powell, E
    Serody, JS
    Wiley, JM
    Shea, TC
    [J]. BONE MARROW TRANSPLANTATION, 1997, 19 (06) : 557 - 563
  • [5] A multicenter study of platelet recovery and utilization in patients after myeloablative therapy and hematopoietic stem cell transplantation
    Bernstein, SH
    Nademanee, AP
    Vose, JM
    Tricot, G
    Fay, JW
    Negrin, RS
    DiPersio, J
    Rondon, G
    Champlin, R
    Barnett, MJ
    Cornetta, K
    Herzig, GP
    Vaughan, W
    Geils, G
    Keating, J
    Messner, H
    Wolff, SN
    Miller, KB
    Linker, C
    Cairo, M
    Hellmann, S
    Ashby, M
    Stryker, S
    Nash, RA
    [J]. BLOOD, 1998, 91 (09) : 3509 - 3517
  • [6] BRADFORD G, 1993, EXP HEMATOL, V21, P1615
  • [7] High-dose etoposide, cyclophosphamide and total body irradiation with allogeneic bone marrow transplantation for resistant acute myeloid leukemia: A study by the north American marrow transplant group
    Brown, RA
    Wolff, SN
    Fay, JW
    Pineiro, L
    Collins, RH
    Lynch, JP
    Stevens, D
    Greer, J
    Herzig, RH
    Herzig, GP
    [J]. LEUKEMIA & LYMPHOMA, 1996, 22 (3-4) : 271 - 277
  • [8] Canals C, 1993, J Hematother, V2, P75, DOI 10.1089/scd.1.1993.2.75
  • [9] AUTOLOGOUS BONE-MARROW TRANSPLANT IN ACUTE MYELOID-LEUKEMIA IN 1ST REMISSION
    CASSILETH, PA
    ANDERSEN, J
    LAZARUS, HM
    COLVIN, OM
    BENNETT, JM
    STADTMAUER, EA
    KAIZER, H
    WEINER, RS
    EDELSTEIN, M
    OKEN, MM
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1993, 11 (02) : 314 - 319
  • [10] CHAO NJ, 1993, BLOOD, V81, P2031